Differential expression of interleukin-17 and interleukin-22 in inflamed and non-inflamed synovium from osteoarthritis patients

Deligne, Claire; Casulli, Sarah; Pigenet, A.; Bougault, Carole; Campillo-Gimenez, Laure; Nourissat, Geoffroy; Bérenbaum, Francis; Elbim, Carole; Houard, Xavier

doi:10.1016/j.joca.2014.12.007

Cited by 84 publications

(76 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding that both IL-6 and IL-8 were more abundant in the synovial fluid of obese hip OA patients, compared to normal-weight patients, supports the notion that increased adiposity is associated with a more inflammatory OA phenotype 2, 22, 23 that may benefit from a different therapeutic approach.…”

Section: Discussionsupporting

confidence: 79%

“…Currently the only treatments for this debilitating condition are analgesics and eventually join replacement. Inflammation is increasingly being recognised as a driver of OA disease pathology thus implicating the synovial environment, including the role of inflammatory cytokines and infiltrated immune cells, in driving the degeneration of cartilage tissue 2–4 . Indeed, synovitis has been demonstrated in OA patients histologically and by MRI and ultrasound imaging 5, 6 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity

Pearson

Herndler‐Brandstetter

Tariq

et al. 2017

Sci Rep

111

103

View full text Add to dashboard Cite

Increasing evidence suggests that inflammation plays a central role in driving joint pathology in certain patients with osteoarthritis (OA). Since many patients with OA are obese and increased adiposity is associated with chronic inflammation, we investigated whether obese patients with hip OA exhibited differential pro-inflammatory cytokine signalling and peripheral and local lymphocyte populations, compared to normal weight hip OA patients. No differences in either peripheral blood or local lymphocyte populations were found between obese and normal-weight hip OA patients. However, synovial fibroblasts from obese OA patients were found to secrete greater amounts of the pro-inflammatory cytokine IL-6, compared to those from normal-weight patients (p < 0.05), which reflected the greater levels of IL-6 detected in the synovial fluid of the obese OA patients. Investigation into the inflammatory mechanism demonstrated that IL-6 secretion from synovial fibroblasts was induced by chondrocyte-derived IL-6. Furthermore, this IL-6 inflammatory response, mediated by chondrocyte-synovial fibroblast cross-talk, was enhanced by the obesity-related adipokine leptin. This study suggests that obesity enhances the cross-talk between chondrocytes and synovial fibroblasts via raised levels of the pro-inflammatory adipokine leptin, leading to greater production of IL-6 in OA patients.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity

Pearson

Herndler‐Brandstetter

Tariq

et al. 2017

Sci Rep

111

103

View full text Add to dashboard Cite

show abstract

“…The inflammatory phenotype of this patient subset is supported by previous reports correlating IL-17 with synovitis in rheumatoid arthritis and OA [27]. However, the presence of synovitis in a significant proportion of OA patients without detectable IL-17 suggests an independent inflammatory component to OA in these patients and further work is necessary to identify the cytokine networks responsible.…”

Section: Discussionsupporting

confidence: 73%

Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype

et al. 2017

View full text Add to dashboard Cite

PurposeOsteoarthritis (OA) is a common and heterogeneous arthritic disorder. Patients suffer pain and their joints are characterized by articular cartilage loss and osteophyte formation. Risk factors for OA include age and obesity with inflammation identified as a key mediator of disease pathogenesis. Interleukin-17A (IL-17) is a pro-inflammatory cytokine that has been implicated in inflammatory diseases such as rheumatoid arthritis. IL-17 can upregulate expression of inflammatory cytokines and adipocytokines. The aim of this study was to evaluate IL-17 levels in the synovial fluid of patients with end-stage knee and hip OA in relation to inflammation- and pain-related cytokines and adipocytokines in synovial fluid and serum, and clinical and radiographic disease parameters.MethodsThis is a cross-sectional study of 152 patients undergoing total hip and knee arthroplasty for OA. IL-17, IL-6, leptin, adiponectin, visfatin, resistin, C-C Motif Chemokine Ligand 2 (CCL2), C-C Motif Chemokine Ligand 7 (CCL7) and nerve growth factor (NGF) protein levels were measured in synovial fluid and serum using enzyme-linked immunosorbent assay (ELISA). Baseline characteristics included age, sex, body mass index, co-morbidities, pain and function, and radiographic analyses (OA features, K&L grade, minimal joint space width).Results14 patients (9.2%) had detectable IL-17 in synovial fluid. These patients had significantly higher median concentrations of IL-6, leptin, resistin, CCL7 and NGF. Osteophytes, sclerosis and minimum joint space width were significantly reduced in patients with detectable IL-17 in synovial fluid. No differences were found in pain, function and comorbidities. IL-17 concentrations in synovial fluid and serum were moderately correlated (r = 0.482).ConclusionThe presence of IL-17 in the synovial fluid therefore identifies a substantial subset of primary end-stage OA patients with distinct biological and clinical features. Stratification of patients on the basis of IL-17 may identify those responsive to therapeutic targeting.

show abstract

“…As stated in the introduction, pathophysiology of OA is very complex due to involvement of multiple factors [18,[20][21][22][23][24][25][26]. Among all these factors, oxidative stress (due to excess generation of free radicals) and inflammation are proven to be the major contributing factors in joint damage and pain [67][68][69][70][71].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Terminalia chebula Extract for Anti-Arthritic Efficacy and Safety in Osteoarthritic Dogs

Murdock¹,

Vega³

et al. 2015

J Veterinar Sci Technol

View full text Add to dashboard Cite

The present investigation was undertaken to assess anti-inflammatory and anti-arthritic efficacy and safety of T. chebula extract (TCE) in moderately osteoarthritic (OA) dogs. Dogs with OA received either 500 mg placebo or 500 mg TCE twice daily for 150 days. On a monthly basis, dogs were given a full physical exam and were evaluated for arthritic pain (overall pain, pain upon limb manipulation, and pain after physical exertion), inflammation (erythrocyte sedimentation rate, ESR), and analysis of complete blood count (CBC) and serum biomarkers of liver (bilirubin, ALT, and AST), kidney (BUN and creatinine), and heart and skeletal muscle (CK) functions. Elbow and stifle joints were radiographed on day 0 and day 150 for evaluation of arthritic progression. Dogs given TCE showed significant (P<0.01) reductions in overall pain, pain upon limb manipulation, and pain after physical exertion by day 90, with maximum effects on day 150 (81.2%, 81.5%, and 84.2%, respectively). A marked reduction in ESR coincided with pain reduction in TCE-treated dogs, which was indicative of anti-inflammatory effect of TCE. Radiographic evidence also indicated slowed progression of OA in joints examined. No significant change occurred in physical parameters, CBC parameters, or serum biomarkers in dogs on placebo or treatment, which suggested that TCE was well tolerated. It can be concluded that TCE, by having many active principles (chebulagic acid, chebulinic acid, corilagin, hydrolysable tannoids, etc.) might have provided antioxidant, anti-inflammatory and anti-arthritic effects in dogs without causing any side effects.

show abstract

Differential expression of interleukin-17 and interleukin-22 in inflamed and non-inflamed synovium from osteoarthritis patients

Cited by 84 publications

References 51 publications

IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity

IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity

Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype

Evaluation of Terminalia chebula Extract for Anti-Arthritic Efficacy and Safety in Osteoarthritic Dogs

Contact Info

Product

Resources

About